Parkinson and Movement Disorders Unit, Department of Neuroscience, University of Padua, Padua, Italy.
Parkinson Foundation Centre of Excellence, King's College Hospital and King's College, London, UK.
BMC Neurol. 2024 Jul 30;24(1):266. doi: 10.1186/s12883-024-03691-3.
The 5-2-1 criteria was developed to facilitate the identification and referral of patients with Parkinson's Disease (PD) inadequately controlled by oral medications. The criterion was not developed to screen patients with PD for device-aided therapy eligibility. The robust design and validation of the 5-2-1 criteria minimizes over or inappropriate referrals, and supports physicians in the timely identification of patients with PD who may warrant further evaluation for treatment optimization. This response letter clarifies concerns raised by Moes et al.
5-2-1 标准旨在促进识别和转介那些经口服药物治疗后仍控制不佳的帕金森病(PD)患者。该标准并非用于筛选有资格接受设备辅助治疗的 PD 患者。5-2-1 标准的稳健设计和验证最大限度地减少了过度或不适当的转诊,并帮助医生及时识别出可能需要进一步治疗优化评估的 PD 患者。这封回复信澄清了 Moes 等人提出的担忧。